380.47
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
United Therapeutics Corp Borsa (UTHR) Ultime notizie
Is United Therapeutics Corporation meeting your algorithmic filter criteria2025 EndofYear Setup & Verified Chart Pattern Signals - Newser
Will United Therapeutics Corporation benefit from rate cutsQuarterly Market Summary & Reliable Price Breakout Alerts - khodrobank.com
Does United Therapeutics Corporation have declining or rising EPSJuly 2025 Closing Moves & Weekly Market Pulse Updates - khodrobank.com
United Therapeutics stock price target raised to $560 from $415 at UBS - Investing.com
Using Bollinger Bands to evaluate United Therapeutics Corporation2025 Dividend Review & Safe Capital Investment Plans - Newser
What’s next for United Therapeutics Corporation stock price2025 Growth vs Value & Daily Momentum Trading Reports - Newser
How hedge fund analytics apply to United Therapeutics Corporation stock2025 Bull vs Bear & Verified Entry Point Detection - Newser
United Therapeutics Corporation (NASDAQ:UTHR) Surges 38% Yet Its Low P/E Is No Reason For Excitement - simplywall.st
Detecting support and resistance levels for United Therapeutics Corporation2025 Technical Overview & Accurate Intraday Trade Tips - Newser
Mannkind Corporation shares rise 1.22% premarket after United Therapeutics' drug Tyvaso shows significant lung function improvement. - AInvest
Is United Therapeutics Corporation forming a bottoming baseJuly 2025 Pullbacks & Real-Time Chart Pattern Alerts - Newser
Does United Therapeutics Corporation show high probability of rebound2025 Big Picture & High Conviction Buy Zone Picks - Newser
Is United Therapeutics Corporation stock entering bullish territoryDividend Hike & Daily Entry Point Trade Alerts - Newser
Can machine learning forecast United Therapeutics Corporation recovery2025 Valuation Update & Long Hold Capital Preservation Tips - Newser
How to build a dashboard for United Therapeutics Corporation stockWall Street Watch & Daily Stock Trend Watchlist - Newser
Is United Therapeutics Corporation a turnaround storyMarket Risk Report & Expert Verified Movement Alerts - khodrobank.com
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results - Stocktwits
United Therapeutics Corporation’s volatility index tracking explainedPortfolio Growth Summary & Intraday High Probability Setup Alerts - Newser
United Therapeutics: On the Rise? - timothysykes.com
Why United Just Catapulted 39%, Pulling Two Rivals With It - Investor's Business Daily
United Therapeutics Shares Soar: Will Momentum Last? - StocksToTrade
Moving Averages: Is United Therapeutics Corporation stock influenced by commodity prices2025 Pullback Review & High Accuracy Swing Trade Signals - khodrobank.com
United Therapeutics Shares Surge on Strong Lung-Drug Trial Results - citybiz
United Therapeutics surges as Tyvaso succeeds in IPF trial: should you invest? - CryptoRank
United Therapeutics stock jumps as Jefferies raises price target on IPF study - Investing.com
United Therapeutics stock hits all-time high on successful drug trial - The Business Journals
UBS Lifts United Therapeutics’ Price Target to Drive Optimism - StocksToTrade
UBS Lifts United Therapeutics Price Target Amid Positive Study Results - timothysykes.com
United’s Tyvaso surprise in IPF potentially opens $4B market - BioWorld MedTech
Why Is United Therapeutics Stock Rallying On Tuesday?United Therapeutics (NASDAQ:UTHR) - Benzinga
United Therapeutics stock hits all-time high at $419.63 - Investing.com
United Therapeutics shares surge as lung disease drug meets main study goal - TradingView
PepsiCo, United Therapeutics Lead Market Cap Stock Movers on Tuesday - Investing.com
United Therapeutics shares surge after Tyvaso IPF trial hits key goal - MSN
United Therapeutics’ Stunning Leap: What’s Behind It? - StocksToTrade
United Therapeutics' TETON-2 Trial Shows Tyvaso Improves Lung Function In IPF Patients - Nasdaq
PepsiCo, Ionis Pharma, United Therapeutics - TradingView
United Therapeutics Corporation announces Teton-2 pivotal study of Tyvaso meets primary endpoint for the treatment of idiopathic pulmonary fibrosis - MarketScreener
United Therapeutics posts Tyvaso trial win (UTHR:NASDAQ) - Seeking Alpha
United Therapeutics Announces Positive TETON-2 Study Results - TipRanks
95.6mL Lung Function Improvement: United Therapeutics' Tyvaso Achieves Breakthrough in IPF Treatment Trial - Stock Titan
Published on: 2025-09-01 20:26:35 - Newser
Published on: 2025-09-01 19:48:53 - Newser
What is United Therapeutics Corporation’s valuation compared to sectorPortfolio Return Report & Weekly Market Pulse Alerts - khodrobank.com
Measuring United Therapeutics Corporation’s beta against major indicesJuly 2025 Review & Risk Controlled Swing Trade Alerts - Newser
United Therapeutics Corporation Rebound Backed by Sentiment Shift getLinesFromResByArray error: size == 0 - 강소기업뉴스
Using flow based indicators on United Therapeutics CorporationQuarterly Growth Report & Fast Gain Swing Alerts - Newser
United Therapeutics Corporation Recovery Gathers Momentum on Chart Signals getLinesFromResByArray error: size == 0 - kangso.co.kr
Will United Therapeutics Corporation rebound enough to break evenWeekly Stock Report & Low Volatility Stock Recommendations - Newser
Tick level data insight on United Therapeutics Corporation volatilityBear Alert & Momentum Based Trading Ideas - Newser
Momentum divergence signals in United Therapeutics Corporation chart2025 Earnings Impact & Precise Swing Trade Alerts - Newser
Published on: 2025-08-31 13:32:31 - Newser
Candlestick signals on United Therapeutics Corporation stock todayDividend Hike & Safe Capital Growth Tips - Newser
Does United Therapeutics Corporation qualify in momentum factor screeningTrade Analysis Report & Community Consensus Trade Signals - Newser
What MACD signals say about United Therapeutics CorporationShare Buyback & AI Powered Market Entry Ideas - Newser
Published on: 2025-08-30 23:59:10 - Newser
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):